MS
Morgan Stanley
(NYSE: MS)
Balfour Capital Group has issued a buy recommendation
for Morgan Stanley (MS) on October 21st, 2025
Morgan Stanley is a global financial services firm with three core franchises:
- Wealth Management (incl. E*TRADE & workplace solutions).
- Institutional Securities (investment banking & capital markets, sales & trading, research).
- Investment Management (public & private markets strategies).
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $155.13 on October 21st, 2025.
- Our designated price target stands at $xxx,00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q3 EARNING REPORT
A Q3 report evaluates company financials for investors.
Balfour Capital Group wants to clarify that our recommendation to Buy Morgan Stanley (NYSE: MS) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
AZO
AutoZone Inc
(NYSE: AZO)
Balfour Capital Group has issued a buy recommendation
for AutoZone Inc (AZO) on October 20th, 2025
AutoZone is a leading retailer and distributor of automotive replacement parts and accessories serving both DIY (retail) and DIFM/professional (commercial) customers across the U.S., Mexico, and Brazil. It sells new and remanufactured hard parts, maintenance items, accessories, and related products through thousands of stores and online channels.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $3.965,00 on October 20th, 2025.
- Our designated price target stands at $4.500,00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
Balfour Capital Group wants to clarify that our recommendation to Buy AutoZone Inc (NYSE: AZO) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
WEIR
Weir Group PLC
(LSE: WEIR)
Balfour Capital Group has issued a buy recommendation
for Weir Group PLC (WEIR) on October 6th, 2025
Weir is a UK-based provider of mining technology and engineered equipment focused on comminution (crushing & grinding), classification, slurry pumping/transport, tailings & dewatering, plus wear parts and ground-engaging tools (brands include Warman, GEHO, Cavex, Enduron and ESCO). It operates through two segments: Minerals and ESCO.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $2.848,00 on October 6th, 2025.
- Our designated price target stands at $3.305,00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
Balfour Capital Group wants to clarify that our recommendation to Buy Weir Group PLC (LSE: WEIR) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
VEEV
Veeva Systems Inc.
(NYSE: VEEV)
Balfour Capital Group has issued a buy recommendation
for Veeva Systems Inc. (VEEV) on October 6th, 2025
Veeva is a public-benefit corporation that provides cloud software, data and consulting for the global life sciences industry. Its platforms (e.g., Vault CRM, Vault content/quality/regulatory suites and Veeva Data Cloud) power clinical, regulatory, quality and commercial workflows for pharma, biotech and med-tech customers.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $296.28 on October 6th, 2025.
- Our designated price target stands at $345.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2026 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
Balfour Capital Group wants to clarify that our recommendation to Buy Veeva Systems Inc. (NYSE: VEEV) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
CTVA
Corteva Inc
(NYSE: CTVA)
Balfour Capital Group has issued a buy recommendation
for Corteva Inc (CTVA) on October 6th, 2025
Corteva is a global ag-tech company focused on two segments: Seeds (Pioneer and other brands; biotech and conventional traits for corn/soy and other crops) and Crop Protection (herbicides, insecticides, fungicides, and biologicals sold in 110+ countries). In 2024 it generated $16.9B in net sales. Management announced plans on Oct 1, 2025 to split Seeds and Crop Protection into two independent public companies by 2H26 (seed ~57% of 2024 sales).
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $63.37 on October 6th, 2025.
- Our designated price target stands at $94.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
Balfour Capital Group wants to clarify that our recommendation to Buy Corteva Inc (NYSE: CTVA) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BE
Bloom Energy Corporation
(NYSE: BE)
Balfour Capital Group has issued a buy recommendation
for Bloom Energy Corporation (BE) on October 6th, 2025
Bloom Energy designs and manufactures solid-oxide fuel cell (SOFC) systems (the “Energy Server®”) that generate on-site electricity from fuels such as natural gas, biogas, or hydrogen without combustion, aiming for resilient, lower-carbon power for enterprises and data centers; Bloom also sells solid-oxide electrolyzers for hydrogen.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $90.29 on October 6th, 2025.
- Our designated price target stands at $115.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
Balfour Capital Group wants to clarify that our recommendation to Buy Bloom Energy Corporation (NYSE: BE) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
RCAT
Red Cat Holdings Inc
(NASDAQ: RCAT)
Balfour Capital Group has issued a buy recommendation
for Red Cat Holdings Inc (RCAT) on October 6th, 2025
Red Cat is a U.S. –based drone/robotics company focused on defense and national security. Through subsidiaries Teal Drones and FlightWave Aerospace, it designs and manufactures small unmanned aircraft systems (sUAS) and related “family of systems, ” led by the Black Widow SRR platform; it also develops command-and-control and maritime unmanned systems (Blue Ops USVs).
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $12.89 on October 6th, 2025.
- Our designated price target stands at $21.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
Balfour Capital Group wants to clarify that our recommendation to Buy Red Cat Holdings Inc (NASDAQ: RCAT) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
GSK
GSK plc
(NYSE: GSK)
Balfour Capital Group has issued a buy recommendation
for GSK plc (GSK) on September 24th, 2025
GSK plc (formerly GlaxoSmithKline) is a British multinational pharmaceutical and biotechnology company.
- Its operations are primarily focused on specialty medicines, vaccines, and general medicines.
- In 2022, GSK spun off its consumer health / over-the-counter business into a separate company, Haleon plc, allowing GSK to focus more on R&D, pharmaceuticals, and vaccines.
- Its R&D strategy currently emphasizes four core therapeutic areas: respiratory, immunology & inflammation, oncology, and infectious diseases / HIV.
- GSK aims to “intervene early to prevent and change the course of disease, ” leveraging science, technology, and innovation.
- As of its 2024 reporting, GSK reported group turnover of £31.4 billion, with segments: Specialty Medicines ~£11.8 bn, Vaccines ~£9.1 bn, General Medicines ~£10.4 bn.
- In 2024, GSK also announced a £2 billion share buyback program and raised its long- term sales target (to > £40 bn by 2031).
- In its FY 2024 performance, specialty medicines were a growth driver (+19% vs prior year), vaccines had a decline (–4% on constant exchange rates) while general medicines grew modestly (+6%).
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $40.52 on September 24th, 2025.
- Our designated price target stands at $65.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
Balfour Capital Group wants to clarify that our recommendation to Buy GSK PLC (NYSE: GSK) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
AZN
AstraZeneca
(NASDAQ: AZN)
Balfour Capital Group has issued a buy recommendation
for AstraZeneca (AZN) on September 24th, 2025
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology
company.
- It researches, develops, manufactures and commercializes prescription medicines in major therapeutic areas including oncology, cardiovascular, renal & metabolic (CVRM), respiratory, inflammation & autoimmunity, neuroscience, infection, and rare diseases.
- Through acquisitions (e.g. Alexion) and internal R&D, AstraZeneca has strengthened its portfolio in immunology and rare diseases.
- It operates globally, with R&D centers in Cambridge (UK), Gothenburg (Sweden), Gaithersburg (Maryland, US), and others.
- The company also has a listing on U.S. via AZN, in addition to its primary London / UK listing.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $75.97 on September 24th, 2025.
- Our designated price target stands at $110.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
Balfour Capital Group wants to clarify that our recommendation to Buy AstraZeneca (NASDAQ: AZN) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ATHE
Alterity Therapeutics Ltd
(NASDAQ: ATHE)
Balfour Capital Group has issued a buy recommendation
for Alterity Therapeutics Ltd (ATHE) on September 23rd, 2025
Alterity Therapeutics is a clinical-stage biotech developing small-molecule therapies for neurodegenerative diseases. Its lead candidate ATH434 is an oral “iron chaperone” designed to reduce pathological α-synuclein aggregation by normalizing brain iron; it’s in Phase 2 for Multiple System Atrophy (MSA), a Parkinsonian disorder, and has U.S. FDA Fast Track for MSA. HQ in Melbourne with a U.S. presence in San Francisco.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $4.42 on September 23rd, 2025.
- Our designated price target stands at $7.40
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
Balfour Capital Group wants to clarify that our recommendation to Buy Alterity Therapeutics Ltd (NASDAQ: ATHE) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
